FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129822461> ?p ?o ?g. }

• W3129822461 endingPage "05" @default.
• W3129822461 startingPage "PS14" @default.
• W3129822461 abstract "Abstract Background: Cutaneous Metastases (CM) are an infrequent presentation of advanced solid tumors and are usually associated with symptoms of pain, pruritus, and secondary infections, all of which negatively affect quality of life and result in additional morbidity. Systemic chemotherapy, advanced wound care, topical agents, cryo-, electro-, photodynamic-, laser and intralesional therapies have been limited by inconsistent efficacy, inconvenience, or toxicity. In this open-label phase 1/2 clinical trial, submicron particle paclitaxel in an anhydrous base (SOR007) was evaluated for topical treatment of CM from breast cancer (n=21), leiomyosarcoma (n=1) and Paget’s disease (n=1). Previously, in vitro, in vivo, and clinical studies demonstrated penetration of paclitaxel into the dermis with the silicone-based anhydrous producing subtoxic plasma levels in GLP toxicology studies and early clinical trials. Trial Design: The phase 1/2 open label trial evaluated 3 doses of SOR007 (0.15%, 1.0%, 2.0%). Approximately 0.5 grams (1 FTU) of SOR007 per 50 cm2 treatment area was applied BID during a 3+3 dose-rising phase for 28 days (n=10) or a dose-expansion phase at 2% strength BID for 28 days (n=2) or 56 days (n=11) unless discontinuation became necessary due to clinical course of the underlying disease. Results: At least one eligible lesion was treated per subject and classified per RECIST 1.1. In the 28-day application group, 10 subjects were treated and in the 56-day application group, 11 subjects were treated. Lesion response is summarized in the table below for data to date. Lesion response was evaluated within 2 weeks of last treatment day in most subjects. Conclusions: SOR007 was safe when applied to CM lesions. SOR007 resulted in decreased lesion progression or reduced lesion area in the majority of CM subjects. These clinical benefits became more consistent and pronounced at 2% strength with longer treatment suggesting a dose/duration response. Lesion pain reduction is also suggested from the study. Additional clinical research with more subjects and longer treatment periods is in the early planning stage. Lesion ResponseLesion response by SUBJECTLesion response by SUBJECTLesion response by INDIVIDUAL LESIONLesion response by INDIVIDUAL LESIONDose-rising 0.15%, 1%, 2% & Dose expansion 2%Dose-expansion 2%Dose-rising 0.15%, 1%, 2% & Dose expansion 2%Dose-expansion 2%BID x 28 daysBID x 56 daysBID x 28 daysBID x 56 daysN (subjects or lesions)8111823Complete Response0% (0/8)9.1% (1/11)5.5% (1/18)26% (6/23)Objective Response Rate13% (1/8)45% (5/11)17% (3/18)43% (10/23)No lesion progression in evaluable subjects 63% (5/8)82% (9/11)61% (11/18)83% (19/23) Citation Format: Mario E Lacouture, Julie E Lang, Sant Chawla, Shari Goldfarb, Alina Markova, Alexander Pan, Rose Marie Cavanna-Mast, Peter Mast, Christopher Savoie, Gere diZerega. Phase 1/2 clinical trial of a topical submicron particle paclitaxel (SOR007) for the treatment of cutaneous metastases [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-05." @default.
• W3129822461 created "2021-03-01" @default.
• W3129822461 creator A5002599922 @default.
• W3129822461 creator A5002737439 @default.
• W3129822461 creator A5027463112 @default.
• W3129822461 creator A5035689503 @default.
• W3129822461 creator A5037808694 @default.
• W3129822461 creator A5038774956 @default.
• W3129822461 creator A5038881654 @default.
• W3129822461 creator A5042880438 @default.
• W3129822461 creator A5072181104 @default.
• W3129822461 creator A5073906112 @default.
• W3129822461 date "2021-02-15" @default.
• W3129822461 modified "2023-09-27" @default.
• W3129822461 title "Abstract PS14-05: Phase 1/2 clinical trial of a topical submicron particle paclitaxel (SOR007) for the treatment of cutaneous metastases" @default.
• W3129822461 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-05" @default.
• W3129822461 hasPublicationYear "2021" @default.
• W3129822461 type Work @default.
• W3129822461 sameAs 3129822461 @default.
• W3129822461 citedByCount "0" @default.
• W3129822461 crossrefType "journal-article" @default.
• W3129822461 hasAuthorship W3129822461A5002599922 @default.
• W3129822461 hasAuthorship W3129822461A5002737439 @default.
• W3129822461 hasAuthorship W3129822461A5027463112 @default.
• W3129822461 hasAuthorship W3129822461A5035689503 @default.
• W3129822461 hasAuthorship W3129822461A5037808694 @default.
• W3129822461 hasAuthorship W3129822461A5038774956 @default.
• W3129822461 hasAuthorship W3129822461A5038881654 @default.
• W3129822461 hasAuthorship W3129822461A5042880438 @default.
• W3129822461 hasAuthorship W3129822461A5072181104 @default.
• W3129822461 hasAuthorship W3129822461A5073906112 @default.
• W3129822461 hasConcept C121608353 @default.
• W3129822461 hasConcept C126322002 @default.
• W3129822461 hasConcept C126894567 @default.
• W3129822461 hasConcept C141071460 @default.
• W3129822461 hasConcept C16005928 @default.
• W3129822461 hasConcept C203092338 @default.
• W3129822461 hasConcept C2776694085 @default.
• W3129822461 hasConcept C2777292972 @default.
• W3129822461 hasConcept C2777501473 @default.
• W3129822461 hasConcept C2778715236 @default.
• W3129822461 hasConcept C2780400711 @default.
• W3129822461 hasConcept C2781464078 @default.
• W3129822461 hasConcept C31760486 @default.
• W3129822461 hasConcept C500558357 @default.
• W3129822461 hasConcept C530470458 @default.
• W3129822461 hasConcept C535046627 @default.
• W3129822461 hasConcept C71924100 @default.
• W3129822461 hasConcept C90924648 @default.
• W3129822461 hasConceptScore W3129822461C121608353 @default.
• W3129822461 hasConceptScore W3129822461C126322002 @default.
• W3129822461 hasConceptScore W3129822461C126894567 @default.
• W3129822461 hasConceptScore W3129822461C141071460 @default.
• W3129822461 hasConceptScore W3129822461C16005928 @default.
• W3129822461 hasConceptScore W3129822461C203092338 @default.
• W3129822461 hasConceptScore W3129822461C2776694085 @default.
• W3129822461 hasConceptScore W3129822461C2777292972 @default.
• W3129822461 hasConceptScore W3129822461C2777501473 @default.
• W3129822461 hasConceptScore W3129822461C2778715236 @default.
• W3129822461 hasConceptScore W3129822461C2780400711 @default.
• W3129822461 hasConceptScore W3129822461C2781464078 @default.
• W3129822461 hasConceptScore W3129822461C31760486 @default.
• W3129822461 hasConceptScore W3129822461C500558357 @default.
• W3129822461 hasConceptScore W3129822461C530470458 @default.
• W3129822461 hasConceptScore W3129822461C535046627 @default.
• W3129822461 hasConceptScore W3129822461C71924100 @default.
• W3129822461 hasConceptScore W3129822461C90924648 @default.
• W3129822461 hasIssue "4_Supplement" @default.
• W3129822461 hasLocation W31298224611 @default.
• W3129822461 hasOpenAccess W3129822461 @default.
• W3129822461 hasPrimaryLocation W31298224611 @default.
• W3129822461 hasRelatedWork W2077655419 @default.
• W3129822461 hasRelatedWork W2090299372 @default.
• W3129822461 hasRelatedWork W2100029565 @default.
• W3129822461 hasRelatedWork W2126237794 @default.
• W3129822461 hasRelatedWork W2130626169 @default.
• W3129822461 hasRelatedWork W2378059478 @default.
• W3129822461 hasRelatedWork W2466043692 @default.
• W3129822461 hasRelatedWork W2886193299 @default.
• W3129822461 hasRelatedWork W2921988831 @default.
• W3129822461 hasRelatedWork W3032618052 @default.
• W3129822461 hasVolume "81" @default.
• W3129822461 isParatext "false" @default.
• W3129822461 isRetracted "false" @default.
• W3129822461 magId "3129822461" @default.
• W3129822461 workType "article" @default.